Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer

This article was originally published here

ATHENA is the first front-line switch maintenance study designed to show PARP monotherapy and PARP/PD-1 combination therapy in one study design. “The completion of target patient enrollment in

The post Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply